Ventilator-associated pneumonia (VAP) Market Research Report- Forecast To 2023

Ventilator-associated pneumonia (VAP) Market Research Report- Forecast To 2023

ID: MRFR/HC/0868-HCRR | September, 2018 | Region: Global | 110 pages | Half-Cooked Research Reports

Global Ventilator-Associated Pneumonia Market Research Report Diagnosis (Clinical, Radiological, Microbiological, Others), Mode of Treatment (Home Care, Hospital Care, Other), End-User (Hospitals & Clinics, Research Centers) - Global Forecast Till 2023


Market Scenario


Ventilator-associated pneumonia is a type of lung infection caused to patients who are on ventilators. Ventilator-associated pneumonia is caused mainly due to lung disease, neurologic disease, and trauma to critically ill persons. Diagnosing VAP requires aggressive surveillance combined with the radiographic examination, bedside examination, and microbiologic examinations of respiratory secretions. Growing Intensive Care Unit Admissions due to rising prevalence of respiratory diseases, rising number of ICU beds and high incidence of traumatic injuries provides favorable backgrounds for the market to grow. According to CDC in 2013, there were 2.8 million traumatic brain injury visits to emergency department and hospitals. The emergency department visits of brain injury patients increased by 47% from 2007. Thus, increasing incidence of TBI drives the growth of the market. Furthermore, increasing geriatric population is likely to fuel the market to grow.  According to the U.S. Census Bureau in 2015, 47.8 million people were 65 years or older, and in 2060, 98.2 million are expected to be 65 years or older.  Such increasing trend in the geriatric population provides favorable backgrounds for the market to grow.


However, factors such as expensive diagnostic tests, high ventilator charges, inappropriate reimbursement scenario, risks associated with ventilators are expected to restrict the market growth during the forecast period.


Segmentation


The global Ventilator-associated pneumonia market is segmented on the basis of diagnosis, mode of treatment, and end-user. The Ventilator-associated pneumonia market, by diagnosis categorized into Clinical Examination, Radiological Examination, Microbiological Analysis and others. Microbiological Analysis is further sub-segmented into Blood and pleural fluid cultures, Nonquantitative or semi-quantitative airway sampling and Quantitative cultures of airway specimens. Mode of treatment segment is segmented into Homecare, Hospital care, and others. On the basis of end-user, the market is segmented into Hospitals & Clinics, Research centers, Ambulatory Care Centers and Emergency Medical Services (EMS).      


On the basis of region, the global Ventilator-associated pneumonia market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players for the global Ventilator-associated pneumonia market Merck & Co., Inc. (U.S.), Adenium Biotech ApS (Denmark), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Austria) and other.


Regional Market Summary


Global Ventilator-associated pneumonia Market Share (%), by Region, 2017


 Ventilator-associated pneumonia Market Share


Sources:  The Asian Development Bank, the U.S. Census Bureau,


The Ventilator-associated pneumonia market is dominated by North America owing to the rising geriatric population within the region. The U.S. Census Bureau projected that in 2060, 19.7 million would be of age 85 or older. This influences the growth of this market in this region.


It is estimated that Europe stood second in the global Ventilator-associated pneumonia market owing to increasing prevalence of lung diseases. According to European respiratory society, more than 50% of deaths are due to lung diseases. Thus, increasing prevalence of lung diseases in this region influences the growth of this market in this region.


Asia Pacific was projected to be the fastest growing region for the global Ventilator-associated pneumonia market in 2017. The rising geriatric population, increasing healthcare expenditure and growing respiratory disorders in Asia is expected to drive market growth in this region. According to The Asian Development Bank (ADB), the geriatric population in Asia is estimated to reach 923 million by 2050. Thus, this provides favorable backgrounds for the Ventilator-associated pneumonia market to grow.


The Middle East and Africa holds the least share in the global Ventilator-associated pneumonia market due to the presence of stringent government policies, poor economies, under-developed healthcare infrastructure and low penetration of healthcare services, especially within the African region.


Research Methodology


Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the global Ventilator-associated pneumonia market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.

Market Segmentation and Key Market Players


Global Ventilator-associated pneumonia Market, by Diagnosis



  • Clinical Examination

  • Radiological Examination

  • Microbiological Analysis

    • Blood and pleural fluid cultures

    • Nonquantitative or semi quantitative airway sampling

    • Quantitative cultures of airway specimens.



  • Others


Global Ventilator-associated pneumonia Market, by mode of Mode of treatment



  • Home care

  • Hospital care

  • Others


Global Ventilator-associated pneumonia market, by End User



  • Hospitals & Clinics

  • Research centers

  • Ambulatory Care Centers

  • Emergency Medical Services (EMS)


Global Ventilator-associated pneumonia Market, by Region



  • The Americas

  • Europe

  • Asia Pacific

  • The Middle East & Africa


Global Ventilator-associated pneumonia Market, by Key Players



  • Merck & Co., Inc. (US),

  • Adenium Biotech ApS (Denmark),

  • AstraZeneca (UK),

  • MedImmune (US),

  • Nabriva Therapeutics AG

  • Others


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Ventilator-associated pneumonia Market, by Diagnosis

6.1 Introduction

6.2 Clinical Examination

6.3 Radiological Examination

6.4 Microbiological Analysis

6.4.1 Blood and pleural fluid cultures

6.4.2 Nonquantitative or semi-quantitative airway sampling

6.4.3 Quantitative cultures of airway specimens.

6.5 Others

Chapter 7. Global Ventilator-associated pneumonia Market, by mode of treatment

7.1 Introduction

7.2 Homecare

7.3 Hospital care

7.4 Others

Chapter 8. Global Ventilator-associated pneumonia market, by End-User

8.1 Introduction

8.2 Hospitals & Clinics

8.3 Research centers

8.4 Ambulatory Care Centers

8.5 Emergency Medical Services (EMS)

Chapter 9. Global Ventilator-associated pneumonia Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Merck & Co., Inc.

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 Adenium Biotech ApS

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 AstraZeneca

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 MedImmune

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Nabriva Therapeutics AG

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Ventilator-associated pneumonia Market Industry Synopsis, 2018–2023

Table 2 Global Ventilator-associated pneumonia Market Estimates & Forecast, 2018–2023, (USD Million)

Table 3 Global Ventilator-associated pneumonia Market, by Region, 2018–2023, (USD Million)

Table 5 Global Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 6 Global Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 7 Global Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million

Table 9 North America Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 10 North America Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 11 North America Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)

Table 11 U.S. Ventilator-associated pneumonia Market, by Type, 2018–2023, (USD Million)

Table 13 U.S. Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 14 U.S. Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 15 U.S. Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)

Table 16 Canada Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 17 Canada Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 18 Canada Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)

Table 20 South America Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 21 South America Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 22 South America Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)

Table 24 Europe Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 25 Europe Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 26 Europe Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)

Table 28 Western Europe Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 29 Western Europe Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 30 Western Europe Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)

Table32 Eastern Europe Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 33 Eastern Europe Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 34 Eastern Europe Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)

Table 36 Asia Pacific Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 37 Asia Pacific Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 38 Asia Pacific Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)

Table 40 The Middle East & Africa Ventilator-associated pneumonia Market, by Diagnosis, 2018–2023, (USD Million)

Table 41 The Middle East & Africa Ventilator-associated pneumonia Market, by Mode of treatment, 2018–2023, (USD Million)

Table 42 The Middle East & Africa Ventilator-associated pneumonia Market, by End-User, 2018–2023, (USD Million)



LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Ventilator-associated pneumonia Market

Figure 3 Market Dynamics for Global Ventilator-associated pneumonia Market

Figure 4 Global Ventilator-associated pneumonia Market Share, by Diagnosis 2017

Figure 5 Global Ventilator-associated pneumonia Market Share, by Mode of treatment 2017

Figure 6 Global Ventilator-associated pneumonia Market Share, by End-User, 2017

Figure 7 Global Ventilator-associated pneumonia Market Share, by Region, 2017

Figure 8 North America Ventilator-associated pneumonia Market Share, by Country, 2017

Figure 9 Europe Ventilator-associated pneumonia Market Share, by Country, 2017

Figure 10 Asia Pacific Ventilator-associated pneumonia Market Share, by Country, 2017

Figure 11 Middle East & Africa Ventilator-associated pneumonia Market Share, by Country, 2017

Figure 11 Global Ventilator-associated pneumonia Market: Company Share Analysis, 2017 (%)

Figure 13 MERCK & CO., INC.: Key Financials

Figure 14 MERCK & CO., INC.: Segmental Revenue

Figure 15 MERCK & CO., INC.: Geographical Revenue

Figure 16 Adenium Biotech ApS: Key Financials

Figure 17 Adenium Biotech ApS: Segmental Revenue

Figure 18 Adenium Biotech ApS: Geographical Revenue

Figure 19 AstraZeneca: Key Financials

Figure 20 AstraZeneca: Segmental Revenue

Figure 21 AstraZeneca: Geographical Revenue

Figure 22 MedImmune: Key Financials

Figure 23 MedImmune: Segmental Revenue

Figure 24 MedImmune: Geographical Revenue

Figure 28 Nabriva Therapeutics AG: Key Financials

Figure 29 Nabriva Therapeutics AG: Segmental Revenue

Figure 30 Nabriva Therapeutics AG: Geographical Revenue